Therapeutics Company Announces Major Clinical Collaboration Agreement

Adaptimmune Therapeutics plc, a company in T-cell therapies, and Galapagos NV, recognized for its innovative approaches to drug discovery and development, have announced a clinical collaboration agreement. This partnership focuses on the exclusive licensing option for Adaptimmune's TCR T-cell therapy candidate, uza-cel, specifically targeting head and neck cancer as well as potential future solid tumor indications. This arrangement leverages Galapagos' decentralized manufacturing platform, promising advancements in the efficacy and accessibility of this next-generation therapy. $Adaptimmune Therapeutics(ADAP.US)$